HIF1A and anemia (phenotype): At day 15, the number of reticulocytes/RBCs and the hemoglobin content in the CG-598 treated groups were not changed compared to the vehicle group, although oral treatment of 100 mg/kg PN-3602, a candidate of systemic distributed HIF-1α stabilizers for use of anemia therapy, significantly increased all parameters (Figures 2E–G and Supplementary Figure 2D).